HLTH 2026: GLP-1 costs remain a challenge. A new CVS study aims to identify the right price
Cost and access to GLP-1s remains a challenge, but the benefits of these drugs aren't in doubt. A new study from CVS Health aims to quantify at what price a GLP-1 drug has generated enough savings elsewhere through improved clinical outcomes
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.